These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38327239)

  • 1. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016).
    Guerra A; Costantino C; Martinon-Torres F; Westerholt S; Lambeth C; Chen Z; Lumley J; Marcek T; Johnson D; Wilck M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2310900. PubMed ID: 38327239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DTaP5-HB-IPV-Hib Vaccine (Vaxelis
    Syed YY
    Paediatr Drugs; 2017 Feb; 19(1):69-80. PubMed ID: 28035545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Safety Profile of a New Approved, Fully Liquid DTaP5-HB-IPV-Hib Vaccine.
    Xu J; Stek JE; Ziani E; Liu GF; Lee AW
    Pediatr Infect Dis J; 2019 Apr; 38(4):439-443. PubMed ID: 30882742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparate kinetics in immune response of two different
    Martinón-Torres F; Salamanca de la Cueva I; Horn M; Westerholt S; Bosis S; Meyer N; Cheuvart B; Virk N; Jakes RW; Duchenne M; Van den Steen P
    Hum Vaccin Immunother; 2024 Dec; 20(1):2342630. PubMed ID: 38687024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants ≥ 2 and < 43 months of Age: A phase III, multicenter, active controlled, assessor-blinded, randomized, parallel-group study.
    Nakano T; Hasegawa M; Endo M; Matsuda K; Tamai H
    Vaccine; 2024 Apr; 42(12):3134-3143. PubMed ID: 38582691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.
    Dolhain J; Janssens W; Sohn WY; Dindore V; Mukherjee P
    Expert Rev Vaccines; 2019 Sep; 18(9):921-933. PubMed ID: 31328999
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.
    Silfverdal SA; Icardi G; Vesikari T; Flores SA; Pagnoni MF; Xu J; Liu GF; Stek JE; Boisnard F; Thomas S; Ziani E; Lee AW
    Vaccine; 2016 Jul; 34(33):3810-6. PubMed ID: 27288217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
    Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M
    Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan.
    Nakayama T; Vidor E; Tsuzuki D; Nishina S; Sasaki T; Ishii Y; Mizukami H; Tsuge H
    J Infect Chemother; 2020 Jul; 26(7):651-659. PubMed ID: 32307307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study.
    Romanenko V; Osipova I; Galustyan A; Scherbakov M; Baudson N; Farhi D; Anaya L; Kuriyakose SO; Meyer N; Janssens W
    Hum Vaccin Immunother; 2020 Sep; 16(9):2265-2273. PubMed ID: 32048889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
    Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
    Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
    Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S
    Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib.
    Zinke M; Disselhoff J; ; Gartner B; Jacquet JM
    Hum Vaccin; 2010 Feb; 6(2):189-93. PubMed ID: 20009522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine.
    Lim FS; Han HH; Jacquet JM; Bock HL
    Ann Acad Med Singap; 2007 Oct; 36(10):801-6. PubMed ID: 17987229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.
    Vesikari T; Becker T; Vertruyen AF; Poschet K; Flores SA; Pagnoni MF; Xu J; Liu GF; Stek JE; Boisnard F; Thomas S; Ziani E; Lee AW
    Pediatr Infect Dis J; 2017 Feb; 36(2):209-215. PubMed ID: 27846055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.